Healthcare
Edap Tms S.a.(EDAP)
Live Price
Offline$4.81
-1.84% today
1Y Change
+171.75%
Window
Jun 25, 2025 β Jun 18, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +10.3%
- EPS Growth
- -52.9%
- Dividend Yield
- 0.0%
Coverage: 247 bars Β· Jun 25, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Edap Tms S.a. (EDAP) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $4.81 and up 171.8% across the available one-year price window (Jun 25, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of +10.3%, EPS growth of -52.9%, a dividend yield of 0.0%. What stands out right now is revenue +10.3%, EPS -52.9%, free cash flow -6.3% with operating margin -38.6% and ROIC -49.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EDAP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.3% vs +7.6% peer median
Operating Margin
Below sector median
-38.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +10.3% and EPS is at -52.9%, with operating margin around -38.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | β | -0.7% | -0.2% | β |
2026 Mar 25, 2026 | -56.3% | +1.6% | -4.9% | -11.3% |
2025 Nov 6, 2025 | +42.3% | +1.5% | +6.5% | +20.6% |
Benchmark Edge
EDAP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EDAP
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EDAP Max Drawdown
-35.36%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EDAP and SPY.
Company Overview
Edap Tms S.a.
NASDAQ Global Market
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
- Leadership
- Ryan Rhodes
- IPO Date
- Aug 1, 1997
- Employees
- 310
- Street Address
- Parc dβActivites la Poudrette-Lamartine
- Mailing
- Vaulx-en-Velin, 69120
- Region
- Vaulx-en-Velin, FR
- Reporting Currency
- USD
- Investor Line
- 33 4 72 15 31 50
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 1.7
- Price/Book
- 5.6
Growth
- Revenue
- +10.3%
- EPS
- -52.9%
- Free Cash Flow
- -6.3%
Profitability
- Gross Margin
- 46.1%
- Operating Margin
- -38.6%
- Net Margin
- -44.9%
- ROE
- -111.7%
- ROIC
- -49.2%
Balance Sheet
- Debt/Equity
- 1.43
- Current Ratio
- 1.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.